EagleClaw Capital Managment LLC Purchases 6,277 Shares of Intuitive Surgical, Inc. $ISRG

EagleClaw Capital Managment LLC lifted its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 51.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,527 shares of the medical equipment provider’s stock after purchasing an additional 6,277 shares during the quarter. EagleClaw Capital Managment LLC’s holdings in Intuitive Surgical were worth $7,534,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fairscale Capital LLC raised its stake in Intuitive Surgical by 3.5% during the 3rd quarter. Fairscale Capital LLC now owns 645 shares of the medical equipment provider’s stock worth $279,000 after buying an additional 22 shares during the period. Beaumont Financial Advisors LLC lifted its holdings in Intuitive Surgical by 3.8% during the third quarter. Beaumont Financial Advisors LLC now owns 627 shares of the medical equipment provider’s stock worth $255,000 after acquiring an additional 23 shares in the last quarter. Hughes Financial Services LLC lifted its holdings in Intuitive Surgical by 40.7% during the third quarter. Hughes Financial Services LLC now owns 83 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 24 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co grew its stake in Intuitive Surgical by 1.0% in the first quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after acquiring an additional 25 shares during the period. Finally, Blue Fin Capital Inc. grew its stake in Intuitive Surgical by 0.5% in the first quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after acquiring an additional 25 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent analyst reports. KeyCorp restated an “overweight” rating on shares of Intuitive Surgical in a report on Wednesday, August 12th. Raymond James Financial reiterated an “outperform” rating and set a $480.00 price objective on shares of Intuitive Surgical in a report on Wednesday, October 21st. Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Barclays reiterated an “overweight” rating and issued a $500.00 price objective (up from $485.00) on shares of Intuitive Surgical in a research report on Wednesday, October 21st. Finally, Citigroup lowered their target price on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $493.54.

Insiders Place Their Bets

In other Intuitive Surgical news, Director Gary Guthart sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $457.34, for a total value of $4,573,400.00. Following the sale, the director owned 1,194,530 shares in the company, valued at approximately $546,306,350.20. The trade was a 0.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Wadors sold 1,078 shares of the company’s stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $443.80, for a total value of $478,416.40. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 39,456 shares of company stock worth $17,769,124 in the last 90 days. Company insiders own 0.60% of the company’s stock.

Intuitive Surgical Trading Up 0.8%

ISRG stock opened at $443.59 on Friday. The stock has a 50-day moving average price of $417.59 and a two-hundred day moving average price of $429.98. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The stock has a market cap of $153.77 billion, a PE ratio of 53.64, a price-to-earnings-growth ratio of 3.03 and a beta of 1.45.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.35. The company had revenue of $3.05 billion for the quarter, compared to analyst estimates of $2.91 billion. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same period in the previous year, the company posted $2.40 earnings per share. On average, analysts forecast that Intuitive Surgical, Inc. will post 9.37 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical develops, manufactures and markets robotic-assisted systems for minimally invasive procedures. Its products include da Vinci surgical systems, which allow surgeons to control instruments and a high-definition vision system from a console, as well as the Ion endoluminal system, designed to assist with minimally invasive lung biopsies. The company also provides instruments, accessories, training and support services for its systems. Its technology is used in a range of surgical specialties, including urology, general surgery and gynecology.